feedback

Course Director

Brian I. Rini, MD, FACP
Brian I. Rini, MD, FACP

Cleveland Clinic Foundation/CWRU Lerner College of Medicine
Taussig Cancer Institute
Cleveland, Ohio

Faculty

Sumanta Kumar Pal
Sumanta Kumar Pal, MD

City of Hope
Duarte, California

Nizar M. Tannir
Nizar M. Tannir, MD, FACP

The University of Texas MD Anderson Cancer Center
Houston, Texas

Accredited by

Medical Learning Institute, Inc.

Activity Details

Credit Types:CME
Credit Amount:1.5 Credits
Release Date:2016-Jul-11
Estimated Time for Completion:90 minutes
Registration Required:No
Cost:Free

Activity Description and Educational Objectives

The treatment landscape in renal cell carcinoma (RCC) continues to expand, providing more targeted and immunotherapeutic options for patients with metastatic disease. During this activity, a panel of top experts presents the highlights of the most current clinical data on multikinase inhibitors, other targeted therapies, and immune therapies in the upfront setting and in previously treated patients with RCC, and puts the clinical implications of these data into perspective to guide optimal application of the latest evidence to practice. Going beyond the standard didactic lectures, Dr. Brian I. Rini, course director, engages his colleagues in a stimulating, interactive discussion within the framework of real case scenarios ensuring that the participants receive the information they need to be able to integrate the novel therapies into practice in an evidence-based, patient-centric manner.

Upon completion of this activity, participants should be better able to:
  • Describe the characteristics and mechanism of action of different targeted agents and immunotherapies for RCC
  • Evaluate the recent efficacy and safety findings from clinical trials assessing currently approved and emerging treatment options, including tyrosine kinase inhibitors (TKIs) and other targeted therapies, as well as immune checkpoint blockade therapies, in the upfront setting of RCC and/or in previously treated patients with RCC
  • Cite key ongoing clinical trials assessing the latest therapies and/or combination approaches with targeted therapies and immuno-oncology agents throughout the continuum of advanced RCC
  • Integrate the latest therapies into practice in a timely, evidence-based, and patient-centric manner as part of the management of previously untreated and treated patients with advanced RCC

Target Audience

This activity has been designed to meet the educational needs of medical oncologists, urologic oncologists, and other healthcare professionals involved in the care of patients with renal cell carcinoma.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. A score of 70% or higher is needed to obtain CME credit. There are no pre-requisites and there is no fee to participate in this activity or to receive CME credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Enduring Material
Release and Expiration Dates: July 11, 2016 - July 10, 2017
Time to Complete: 90 minutes

Faculty & Disclosure / Conflict of Interest Policy

Before the activity, all faculty and anyone who is in a position to have control over the content of this activity and their spouse/life partner will disclose the existence of any financial interest and/or relationship(s) they might have with any commercial interest producing healthcare goods/services to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakers bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions. All identified conflicts of interest are thoroughly vetted by Medical Learning Institute, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The associates of Medical Learning Institute, Inc., the accredited provider for this activity, and PVI, PeerView Institute for Medical Education do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this CME activity for any amount during the past 12 months.

Course Director and Moderator
Brian I. Rini, MD, FACP
Professor of Medicine
Cleveland Clinic Foundation/CWRU Lerner College of Medicine
Taussig Cancer Institute
Solid Tumor Oncology & Urology
Cleveland, Ohio

Brian I. Rini, MD, FACP, has a financial interest/relationship or affiliation in the form of:
Consultant for Acceleron Pharma; F. Hoffmann-La Roche Ltd; Novartis Pharmaceuticals Corporation; and Pfizer Inc.
Grant/Research Support from Acceleron Pharma; F. Hoffmann-La Roche Ltd; and Pfizer Inc.

Brian I. Rini, MD, FACP, does intend to discuss either non–FDA-approved or investigational use for the following products/devices: Various targeted agents and immunotherapies alone or in combinations for ​renal cell carcinoma.

Faculty
Sumanta Kumar Pal, MD
Assistant Professor, Genitourinary Malignancies
Department of Medical Oncology & Therapeutics Research
Co-director, Kidney Cancer Program
City of Hope
Duarte, California

Sumanta Kumar Pal, MD, has a financial interest/relationship or affiliation in the form of:
Consultant for Astellas Pharma US, Inc.; Bristol-Myers Squibb Company; Exelixis, Inc.; GSK group of companies; Medivation, Inc.; Novartis Pharmaceuticals Corporation; and Pfizer Inc.
Speakers Bureau participant with Genentech, Inc.

Sumanta Kumar Pal, MD, does intend to discuss either non–FDA-approved or investigational use for the following products/devices: Various targeted agents and immunotherapies alone or in combinations for ​renal cell carcinoma.

Nizar M. Tannir, MD, FACP
Professor and Deputy Chairman
Department of Genitourinary Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, Texas

Nizar M. Tannir, MD, FACP, has a financial interest/relationship or affiliation in the form of:
Consultant for Bristol-Myers Squibb Company; Exelixis, Inc.; GSK group of companies; Nektar; Novartis Pharmaceuticals Corporation; and Pfizer Inc.
Grant/Research Support from Bristol-Myers Squibb Company; Epizyme, Inc.; Exelixis, Inc.; and Novartis Pharmaceuticals Corporation.
Speakers Bureau participant with Bristol-Myers Squibb Company; Exelixis, Inc.; GSK group of companies; Nektar; Novartis Pharmaceuticals Corporation; and Pfizer Inc.
Advisory Board for Bristol-Myers Squibb Company; Exelixis, Inc.; GSK group of companies; Nektar; Novartis Pharmaceuticals Corporation; and Pfizer Inc.

Nizar M. Tannir, MD, FACP, does intend to discuss either non–FDA-approved or investigational use for the following products/devices: Various targeted agents and immunotherapies alone or in combinations for ​renal cell carcinoma.

Peer Reviewer
Amy Goodrich, MSN, CRNP
Johns Hopkins Kimmel Cancer Center
Baltimore, Maryland

Amy Goodrich, MSN, CRNP, has no financial interests/relationships or affiliations in relation to this activity.

Medical Director
Aarati Ranganathan, PhD
PVI, PeerView Institute for Medical Education

Aarati Ranganathan, PhD, has no financial interests/relationships or affiliations in relation to this activity.

Disclaimer

The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient's medical condition. Recommendations for the use of particular therapeutic agents are based on the best available scientific evidence and current clinical guidelines. No bias towards or promotion for any agent discussed in this program should be inferred.

Providership, Credit & Support

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. The Medical Learning Institute, Inc. is accredited by the ACCME to provide continuing medical education for physicians.

The Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Providership
This CME activity is jointly provided by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education.

Support
This activity is supported by an educational grant from Exelixis.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports.

Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView Press or any of its partners, providers, and/or supporters.

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.